Pyxis Oncology, Inc. (PYXS): Price and Financial Metrics
PYXS Price/Volume Stats
| Current price | $1.20 | 52-week high | $5.39 |
| Prev. close | $1.15 | 52-week low | $0.83 |
| Day low | $1.15 | Volume | 281,700 |
| Day high | $1.21 | Avg. volume | 564,899 |
| 50-day MA | $1.07 | Dividend yield | N/A |
| 200-day MA | $2.22 | Market Cap | 74.34M |
PYXS Stock Price Chart Interactive Chart >
Pyxis Oncology, Inc. (PYXS) Company Bio
Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Price Returns
| 1-mo | 11.11% |
| 3-mo | -6.25% |
| 6-mo | -36.84% |
| 1-year | -68.59% |
| 3-year | -51.81% |
| 5-year | N/A |
| YTD | -23.08% |
| 2024 | -13.33% |
| 2023 | 34.33% |
| 2022 | -87.78% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...